Literature DB >> 19491913

Tyrosine kinases as targets for the treatment of rheumatoid arthritis.

Christina D'Aura Swanson1, Ricardo T Paniagua, Tamsin M Lindstrom, William H Robinson.   

Abstract

As critical regulators of numerous cell signaling pathways, tyrosine kinases are implicated in the pathogenesis of several diseases, including rheumatoid arthritis (RA). In the absence of disease, synoviocytes produce factors that provide nutrition and lubrication for the surrounding cartilage tissue; few cellular infiltrates are seen in the synovium. In RA, however, macrophages, neutrophils, T cells and B cells infiltrate the synovium and produce cytokines, chemokines and degradative enzymes that promote inflammation and joint destruction. In addition, the synovial lining expands owing to the proliferation of synoviocytes and infiltration of inflammatory cells to form a pannus, which invades the surrounding bone and cartilage. Many of these cell responses are regulated by tyrosine kinases that operate in specific signaling pathways, and inhibition of a number of these kinases might be expected to provide benefit in RA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491913      PMCID: PMC3401602          DOI: 10.1038/nrrheum.2009.82

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  78 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis.

Authors:  J Lu; T Kasama; K Kobayashi; Y Yoda; F Shiozawa; M Hanyuda; M Negishi; H Ide; M Adachi
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

3.  Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation.

Authors:  Wan-Uk Kim; Soon Suk Kang; Seung-Ah Yoo; Kyung-Hee Hong; Dong-Goo Bae; Mi-Sook Lee; Seung Woo Hong; Chi-Bom Chae; Chul-Soo Cho
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

4.  Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.

Authors:  A Juurikivi; C Sandler; K A Lindstedt; P T Kovanen; T Juutilainen; M J Leskinen; T Mäki; K K Eklund
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

Review 5.  Focal adhesion kinase: a potential target in cancer therapy.

Authors:  Maroesja J van Nimwegen; Bob van de Water
Journal:  Biochem Pharmacol       Date:  2006-09-25       Impact factor: 5.858

Review 6.  RANKL-RANK signaling in osteoclastogenesis and bone disease.

Authors:  Teiji Wada; Tomoki Nakashima; Nishina Hiroshi; Josef M Penninger
Journal:  Trends Mol Med       Date:  2005-12-13       Impact factor: 11.951

7.  Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages.

Authors:  Masato Murakami; Shinobu Iwai; Sachie Hiratsuka; Mai Yamauchi; Kazuhide Nakamura; Yoichiro Iwakura; Masabumi Shibuya
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

8.  Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium.

Authors:  Nobuyuki Watanabe; Kiichiro Ando; Shinichi Yoshida; Sawako Inuzuka; Masaaki Kobayashi; Nobuo Matsui; Takashi Okamoto
Journal:  Biochem Biophys Res Commun       Date:  2002-06-28       Impact factor: 3.575

9.  Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue.

Authors:  Shiva Shahrara; Michael V Volin; Matthew A Connors; G Kenneth Haines; Alisa E Koch
Journal:  Arthritis Res       Date:  2002-01-16

10.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.

Authors:  Oliver Hantschel; Uwe Rix; Uwe Schmidt; Tilmann Bürckstümmer; Michael Kneidinger; Gregor Schütze; Jacques Colinge; Keiryn L Bennett; Wilfried Ellmeier; Peter Valent; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-07       Impact factor: 11.205

View more
  26 in total

Review 1.  Tyrosine kinases in inflammatory dermatologic disease.

Authors:  Ricardo T Paniagua; David F Fiorentino; Lorinda Chung; William H Robinson
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

2.  Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?

Authors:  Alejandro Balsa; Miriam García-Arias
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

Review 3.  Peptide reporters of kinase activity in whole cell lysates.

Authors:  Ding Wu; Juliesta E Sylvester; Laurie L Parker; Guangchang Zhou; Stephen J Kron
Journal:  Biopolymers       Date:  2010       Impact factor: 2.505

4.  Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS.

Authors:  Guangchang Zhou; Xiaoliang Yan; Ding Wu; Stephen J Kron
Journal:  Bioconjug Chem       Date:  2010-10-20       Impact factor: 4.774

5.  A pathogenic relationship between a regulator of the actin cytoskeleton and serum response factor.

Authors:  Angela M Verdoni; Keaton J Schuster; Brian S Cole; Akihiro Ikeda; Winston W Kao; Sakae Ikeda
Journal:  Genetics       Date:  2010-07-06       Impact factor: 4.562

6.  Activity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads.

Authors:  Gargi Ghosh; Xiaoliang Yan; Stephen J Kron; Sean P Palecek
Journal:  Assay Drug Dev Technol       Date:  2012-09-20       Impact factor: 1.738

Review 7.  Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications.

Authors:  Sabrina Solouki; Avery August; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-05-11       Impact factor: 12.310

8.  A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

Authors:  Tamsin M Lindstrom; William H Robinson
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

9.  Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.

Authors:  Mohamed E Shaker; Khaled R Zalata; Wajahat Z Mehal; Gamal E Shiha; Tarek M Ibrahim
Journal:  Toxicol Appl Pharmacol       Date:  2011-02-24       Impact factor: 4.219

Review 10.  Intracellular signal pathways: potential for therapies.

Authors:  Melissa Mavers; Eric M Ruderman; Harris Perlman
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.